Monthly Update – June 2025

Release Highlights:

Watch CEO, Dr Chris Burns and COO, Dr Rhiannon Jones, discuss what has been happening at Amplia Therapeutics this month here: https://www.youtube.com/watch?...

• Amplia Therapeutics (ASX: ATX) continues to participate in key global oncology and biotech meetings, including at Bio Korea in Seoul and ASCO in Chicago, where the company has presented updated data from its ACCENT trial and received strong interest and encouragement from the medical and investor communities.
• The ACCENT trial of narmafotinib combined with chemotherapy in pancreatic cancer patients has achieved its pre-set goal of 15 partial responses, with over 20 patients still ongoing and more data expected soon; a second trial involving a different chemo combination is in the startup phase with ethics submissions underway.
• Amplia released its FY23–24 annual report and latest quarterly shareholder update, both now accessible via their newly launched website where investors can subscribe to updates and submit questions to the team.